Feb 3, 2025 · Journavx (suzetrigine) is a new non-opioid pain-relieving tablet used to treat short-term (acute) moderate to severe pain. Journavx is a sodium channel blocker that relieves pain by blocking pain-sensing nerves around the body from transmitting pain …

Feb 3, 2025 · Suzetrigine, marketed under the brand name Journavx, is a novel non-opioid analgesic recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe acute pain in adults. Developed by Vertex Pharmaceuticals, it represents the first new class of pain medication approved in over two decades.

Jan 30, 2025 · Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults.

JOURNAVX is an oral treatment indicated for moderate-to-severe acute pain in adults. View info on the mechanism of action, efficacy, safety profile, and dosing. See Important Safety Information and Prescribing Information.

JOURNAVX is a sodium channel blocker indicated for the treatment of moderate to severe acute pain in adults. (1) -----DOSAGE AND ADMINISTRATION----- • Swallow JOURNAVX tablets whole and do not chew or crush. (2.1) • Recommended starting JOURNAVX oral dose is …

Feb 2, 2025 · Journavx (suzetrigine) is commonly taken to treat pain that often comes on quickly and lasts a short time, also called acute pain.

JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain.

Jan 31, 2025 · The FDA on Thursday approved Vertex Pharmaceuticals' Journavx to treat moderate to severe acute pain in adults. Acute pain is short-term pain often caused by surgery, accident or injury.

Journavx is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain.

Mar 14, 2025 · Journavx (suzetrigine) is the first nonopioid pain medication approved by the FDA in 25 years, offering an alternative to opioids for managing moderate to severe acute pain.